Why Is Burden of Care the Biggest Challenge of Cancer Treatment?

Commentary
Video

Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.

CancerNetwork® spoke with Rachel Greenup, MD, MPH, a professor of surgery, the section chief of Breast Surgery, and the codirector of the Center for Breast Cancer at Smilow Cancer Hospital of Yale School of Medicine, about breast cancer treatment during a site visit to Yale School of Medicine. Greenup specializes in patient-centered breast cancer care and reducing the financial, logistical, and emotional burdens associated with treatment, among other things.

Plainly put, Greenup stated that the burden of care is the most difficult aspect of receiving cancer therapy. While the first goal is always to complete treatment and survive, it’s important that patients thrive instead of simply surviving. There are several ways to go about this, but she highlighted reducing the adverse effects of the therapies and surgeries that patients undergo as one of the most important.

An ongoing effort is to keep patients informed on their diagnosis and what it truly means, but also to help them understand all their treatment options so they can make informed decisions.

Transcript:

The biggest challenge with being a [patient with] cancer is often the burden of care. Everybody hears they have cancer, and their first goal is to get through their cancer treatment and to survive, but once the diagnosis has settled in and once treatment has been undergone or completed, patients realize they deserve to thrive after a cancer diagnosis. Making sure we’re reducing not only the [adverse] effects of the therapies we give, the surgeries we perform, but also making sure we keep patients whole, financially, psychologically, and emotionally, is critical to us. We’re studying how to make sure women know what they’re facing, that they’re making informed decisions, and that the collateral damage or [adverse] effects of those treatment decisions don’t leave them worse off than they were prior to their cancer diagnosis.

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Related Content